Form 4: Lyell Immunopharma CEO Lynn Seely Acquires Shares and Options
SEC Form 4 Filing
Lyell Immunopharma's CEO, Lynn Seely, reports acquisition of common stock and options in the company.
Summary
- On February 10, 2025, Lynn Seely, the President and CEO of Lyell Immunopharma, acquired 337,500 shares of common stock.
- Following this transaction, Seely directly owns 537,500 shares of common stock.
- Seely also acquired options to purchase 1,350,000 shares of common stock at an exercise price of $0.5535, expiring on February 9, 2035.
- Additionally, Seely received performance-based options for 168,750 shares, also exercisable at $0.5535 and expiring on February 9, 2035.
- Vesting for both the initial options and restricted stock units begins on August 9, 2025, with subsequent vesting occurring quarterly or monthly, contingent upon continued service.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of insider transactions. The CEO's increased stake could be seen as mildly positive.
Positives
- The CEO's acquisition of shares and options could be interpreted as a positive signal, indicating confidence in the company's future prospects.
Future Outlook
The vesting schedules for the acquired options and restricted stock units suggest a long-term commitment from the CEO.
Industry Context
Form 4 filings are standard disclosures for company insiders and provide transparency into their transactions in the company's securities.
Stakeholder Impact
- Shareholders may view the CEO's increased stake as a positive sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 02/10/2025 | Date of transaction: Acquisition of common stock and options. |
| 08/09/2025 | Initial vesting date for restricted stock units and options. |
| 02/09/2035 | Expiration date for the acquired options. |
| 02/26/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.